No-Cost, On-Demand Primary Human Hepatocyte Pooling Using CryostaX Pellets

Author: Dr. Chris Bohl, Michael Millhollen Posted: 15 June 2018

CryostaX® hepatocytes are created using a patented process that produces unique single-donor cell pellets, allowing unprecedented ease and versatility for custom pooling...

Read more

NADPH RapidStart regeneration system for extended metabolism

Author: Isabelle Nobiron, tebu-bio Posted: 30 May 2018

A post from our EU partner, tebu-bio, on NADPH regeneration for ADME-Tox studies using recombinant CYPs (incl. bactosomes) or cellular fractions (Microsomes, S9)...

Read more

In Vitro DDI Regulatory Guidance Reference Poster

Author: Michael Millhollen Posted: 29 May 2018

Download Sekisui XenoTech’s poster outlining the current FDA, EMA & PMDA guidance experimental details, equations, cut-off values, etc. for in vitro drug-drug interaction studies...

Read more

Maximize Metabolic Activities by Limiting Hepatocyte Cryoinjury

Author: Dr. Chris Bohl, Michael Millhollen Posted: 01 May 2018

Cryopreservation and thawing of primary hepatocytes causes inherent damage to the cells. However, utilizing a single-freeze method for pooling donors is shown to preserve higher metabolic activity...

Read more

Assess catabolic stability of biologics & ADCs with Lysosomes – Characterized test systems

Author: Isabelle Nobiron, tebu-bio Posted: 30 April 2018

A post from our EU partner, tebu-bio, on the characterization of isolated human liver lysosomes, and validating them as test systems for in vitro assessment of catabolic stability of biologics drugs entering the cell by the endosomal–lysosomal pathway...

Read more

No More Water Baths! Simplify Hepatocyte Thaws and Eliminate Contamination

Author: Dr. Chris Bohl, Michael Millhollen Posted: 03 April 2018

By eliminating the need for water baths, a significant source of tissue culture contamination can be removed, efficiency is increased and performance variability is decreased...

Read more

Sekisui XenoTech Adds US and Japanese Support for MATE1 and MATE2-K Drug Transporter Studies

Author: Michael Millhollen Posted: 02 April 2018

Sekisui XenoTech now offers MATE1 and MATE2-K drug transporter evaluation services at our research labs in the USA as well as Japan!

Read more

Sekisui Medical Celebrates its 10th Anniversary

Author: Michael Millhollen Posted: 01 April 2018

It's been 10 years since Sekisui Medical Co., Ltd. was established, the same year XenoTech, LLC was acquired...

Read more

Sekisui XenoTech Named Best In Vitro Drug Metabolism Studies Provider 2018

Author: Michael Millhollen Posted: 27 March 2018

Sekisui XenoTech has been named the Best In Vitro Drug Metabolism Studies Provider in the 2018 Biotechnology Awards. “This awards programme recognises the hard work and dedication of the firms, and the individuals behind them, that are driving innovation in this vital market. It has been my honour to recognise these dedicated professionals and I would like to wish them the very best of fortunes for the future...”

Read more

Choosing a Relevant Small Animal Model for Pharmacokinetic or Toxicity Studies

Author: Dr. Chris Bohl Posted: 01 March 2018

Choosing the most suitable small animal model is crucial for pharmacokinetic and/or toxicology studies in order to get usable, relevant data. Due to potential species-dependent variability in candidate drug metabolism, the decision of which small animal model to utilize may not always be obvious...

Read more

Recombinant CYP Bactosomes: versatile formats for many ADME applications

Author: Isabelle Nobiron, tebu-bio Posted: 25 February 2018

A post from our EU partner, tebu-bio, on Recombinant CYPs, which are commonly used in ADME-Tox studies as in vitro tools, mostly for reaction phenotyping, enzyme inhibition screening, clearance and metabolite ID...

Read more

Insects and Cattle and Sheep, Oh My!

Author: Aaron Hilgedick, Michael Millhollen Posted: 15 February 2018

Over the past two decades, we’ve received a lot of interesting requests for custom tissue preparations here at Sekisui XenoTech. Read about some of the unique species, tissues and cellular preparations as well as characterization assays that we’ve performed...

Read more

Sekisui Named in the 2018 Global 100 World’s Most Sustainable Corporations

Author: Michael Millhollen Posted: 26 January 2018

Our parent company has been selected as one of the 2018 Global 100 Most Sustainable Corporations in the World index (2018 Global 100)!

Read more

Sekisui XenoTech Hiring and Growing to Meet Customer Demand

Author: Michael Millhollen Posted: 08 January 2018

We hired a record number of new staff over the past year in order to meet current demand for our products and services…

Read more

What to Do with Microsome Stable, Low-Turnover Compounds

Author: Dr. Chris Bohl Posted: 07 December 2017

Compounds that exhibit high metabolic stability in hepatocytes and subcellular fractions can be a challenge for ADME scientists. These in vitro drug metabolism test systems are easy to source and use at the bench, and the methods for xenobiotic metabolism in these matrices are largely standardized and accepted by the scientific community, but they are limited to a 4-6 hour window of time when they are metabolically active and can generate quality data. There have been many interesting advances in the field to address these constraints, though...

Read more

Sekisui XenoTech Featured in the Fall Issue of NewsWave

Author: Michael Millhollen Posted: 15 November 2017

Read about our academic roots, how our path led us to being a global contract research organization, and where our path is taking us...

Read more

Initial Impressions of the new Draft FDA DDI Guidance Documents from Sekisui XenoTech

Author: Dr. Brian Ogilvie, Michael Millhollen Posted: 26 October 2017

The FDA has released its new draft guidance for DDI studies. View the documents and learn more about this important release...

Read more

Hepatosure Hepatocytes: the largest donor pool for your DMPK applications

Author: Isabelle Nobiron, tebu-bio Posted: 18 October 2017

HepatoSure® is a pool of human hepatocytes designed to facilitate your DMPK applications. HepatoSure® is best suited for both discovery and development of ADME-Tox study assays where generation and comparison of data is required. Let’s take a closer look...

Read more

Further Research on the Drug-Drug Interaction Between Gemfibrozil and Repaglinide Presented

Author: Michael Millhollen Posted: 27 September 2017

Sekisui XenoTech scientists previously established a gemfibrozil/repaglinide DDI resulting in increased repaglinide and metabolite plasma exposure and a vectoral shift in elimination pathways from biliary to urinary excretion following administration of gemfibrozil in male Sprague-Dawley rats. In that study, negligible effects on liver enzyme activity were observed following gemfibrozil treatment, suggesting that the DDI in rats was unlikely to be caused by P450 or UGT inhibition. In the present study, the potential role of uptake transporter proteins in the interaction was explored in vitro...

Read more

Cold Storage Solution Linked to Lower AO, XO Activity

Author: Michael Millhollen Posted: 22 August 2017

Allopurinol, UW cold storage solution has been shown to reduce aldehyde oxidase and xanthine oxidase activity in common human liver test systems for in vitro drug metabolism studies…

Read more

Considerations in Response to Drug-Drug Interaction Guidances

Author: Michael Millhollen Posted: 17 August 2017

Sekisui XenoTech scientists contributed to the published considerations from the IQ Induction Working Group in response to drug-drug interaction guidances from regulatory agencies...

Read more

URI Drug Transporters Workshop Presentations

Author: Michael Millhollen Posted: 11 August 2017

If you couldn't make it to The University of Rhode Island College of Pharmacy's 5th Annual Transporters in Drug Discovery and Development: Driving Knowledge from Laboratory to Label (TDDD 2017), you can still view our presentations...

Read more

New Division Directors for Core Services and Services Logistics Appointed

Author: Michael Millhollen Posted: 01 August 2017

Following the promotion of Dr. Joanna Barbara, Ph.D., to Vice President of Scientific Operations, Dr. Etsuko Usuki, Ph.D., has been promoted to the position of Division Director for Sekisui XenoTech's Core Services. Andrea Wolff has also been appointed to the newly created position of Division Director for Sekisui XenoTech's Services Logistics...

Read more

Sekisui XenoTech's Analytical Services Department Adds New Instrumentation

Author: Michael Millhollen Posted: 17 July 2017

Sekisui XenoTech's Analytical Services lab provides researchers with custom method development and method validation, dose solution analysis, in vitro and in vivo metabolite profiling studies, small-molecule non-GLP bioanalysis and more utilizing specialized equipment, including a Waters Xevo TQ-S mass spectrometer and Xevo G2-XS quadrupole time-of-flight (QTof) mass spectrometer...

Read more

Considerations When Studying Esterase Activities in the Intestine

Author: Dr. Chris Bohl, Michael Millhollen Posted: 11 July 2017

First-pass metabolism in the gut is commonly associated with CYP450 and UGT enzymes, however, it may be important for you to consider the impact of intestinal esterases on your compound. Utilizing a PMSF-free preparation for your test system maintains high levels of esterase activity to ensure reliable experimental results, but is less useful for CYP450 metabolism studies due to low activities...

Read more

UGT activities, concomitant drugs, and DDI

Author: Michael Millhollen Posted: 20 June 2017

Do you have questions or concerns about how your compound may affect UGT induction and/or inhibition when combined with other therapeutic regiments? We can help address those concerns...

Read more

New range of Pig P450s Bactosomes

Author: Isabelle Nobiron, tebu-bio Posted: 19 June 2017

If you are looking for enzymatic in vitro tools for drug metabolismreaction phenotyping or metabolite generation using a pig model, you may find these newly released Pig Bactosomes from Cypex of interest...

Read more

Metabolite production made fast and easy – BMO Kits

Author: Isabelle Nobiron, tebu-bio Posted: 14 June 2017

Metabolite characterization can be a lengthy process making your in vitro drug testing time consuming and expensive. Whether you are working on phase I or phase II metabolic enzymatic reactions, take a look at these BMO kits which can help you speed up this characterization process...

Read more

New Liver Disease Resource & Other Research Biobank News

Author: Dr. Maciej Czerwinski, Michael Millhollen Posted: 26 May 2017

Download the new FLD progression infographic: Characteristics of Normal and Fatty Liver Disease Tissues, or read about the new gallbladder tissue as well as liver tissue samples from donors diagnosed with steatosis and steatohepatitis along with additional details on NASH and Diabetic donors...

Read more

Big Hepatocytes News!

Author: Michael Millhollen Posted: 10 May 2017

Sekisui XenoTech was issued U.S. Patent No. 9,642,355 for the “CRYOPRESERVATION OF CELLS AND SUBCELLULAR FRACTIONS” and enhanced its catalog of hepatocyte offerings...

Read more

New VP of Scientific Operations and VP of Scientific Consulting Appointed

Author: Michael Millhollen Posted: 04 May 2017

Sekisui XenoTech has appointed Dr. Joanna Barbara as Vice President of Scientific Operations and Dr. Brian Ogilvie as Vice President of Scientific Consulting...

Read more

New Lysosome Catabolism Protocol and Tech Tips

Author: Dr. Chris Bohl, Michael Millhollen Posted: 17 April 2017

New guide available: IgG Catabolism Protocol & Lysosome / Tritosome Technical Tips… 

Read more

Sekisui XenoTech Adds New Drug Transporters to Portfolio

Author: Michael Millhollen Posted: 01 April 2017

Sekisui XenoTech features the most extensive selection of drug transporters and assays available in the world, and now we have added 6 more to the list...

Read more

Sekisui Turns 70 This Month!

Author: Michael Millhollen Posted: 03 March 2017

From a single plastics manufacturing plant in Japan to a diverse, multi-billion-dollar, global family which includes Sekisui XenoTech in Kansas City, Sekisui Chemical Group has positioned itself as a corporate leader in key industries and a strong advocate for environmental issues. XenoTech joined the Sekisui team in 2008 to bring focused expertise on biotransformation and preclinical development consulting to the broad range of pharmaceutical development services offered by Sekisui.

Read more

Sekisui XenoTech Named Best for Pharmaceutical Safety Testing 2017

Author: Michael Millhollen Posted: 02 March 2017

Sekisui XenoTech has been named the Best for Pharmaceutical Safety Testing in the 2017 Biotechnology Awards. “This awards programme recognises the hard work and dedication of the firms, and the individuals behind them, that are driving innovation in this vital market. It has been my honour to recognise these dedicated professionals and I would like to wish them the very best of fortunes for the future...”

Read more

Sekisui XenoTech Adds New Dermal Subcellular Fraction Test Systems

Author: Michael Millhollen Posted: 01 February 2017

Sekisui XenoTech now offers human, minipig, mouse and rat dermal microsomes or S9 fractions as in stock standard test systems for the development of safer new products delivered to or through the skin. Subcellular fractions are widely used in drug discovery and preclinical drug development to evaluate the in vitro metabolism of new therapeutics.

Read more

Pharmaceutical Outsourcing Magazine Interview Nov-Dec 2016

Author: Michael Millhollen Posted: 29 November 2016

Pharmaceutical Outsourcing Magazine interviewed Chris Bohl, PhD, Global Technical Support Manager for Sekisui XenoTech’s Products Division, on the company and what's new...

Read more

Sekisui XenoTech Standardizes Lysosomal Test Systems for Biopharmaceutical Development

Author: Dr. Chris Bohl, Michael Millhollen Posted: 05 October 2016

Sekisui XenoTech now offers hepatic human lysosomes and rat tritosomes as standard test systems. These products contain high concentrations of lysosomal degradative enzymes and constitute advantageous test systems for analysis of catabolism and/or activation for targeted biopharmaceuticals that enter cells through the endosomal-lysosomal pathway...

Read more

Sekisui XenoTech Joins Fight Against Liver Disease

Author: Dr. Maciej Czerwinski, Michael Millhollen Posted: 16 September 2016

Currently, there are no approved therapies for NASH, yet nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) affects 1-in-4 people worldwide. Research BioBank provides disease-defined liver tissue samples and hepatocytes as a convenient human model for hepatic disease research...

Read more

Sekisui XenoTech Featured on Labiotech.EU

Author: Michael Millhollen Posted: 05 July 2016

In the article, titled "Understand which transporters are involved in a drug’s absorption, distribution & excretion," Labiotech.EU's editors collaborated with our team to discuss: "How can you build the best case for a new drug application to the regulatory agencies? Preclinical studies are a crucial part in determining the pharmacokinetics of a drug – and more specifically how it is going to interact with drug transporters. So reaching out to the leading provider and consultant in this area (with strong academic roots) is the logical step at this stage of development..."

Read more

XenoTech Scientists Publish Paper, Present Research Evaluating Ketoconazole and its Alternative Clinical CYP3A4-5 Inhibitors as Inhibitors of Drug Transporters

Author: Michael Millhollen Posted: 25 April 2016

Sekisui XenoTech scientists published a paper in Drug Metabolism and Disposition evaluating Ketoconazole and its alternative clinical CYP3A4-5 inhibitors as inhibitors of drug transporters, and presented their research at a meeting of the Delaware Valley Drug Metabolism Discussion Group (DVDMDG), during a webinar earlier this month, and with a poster at the AAPS/ITC Workshop on Drug Transporters.

Read more

Sekisui XenoTech Fulfills Largest Order To Date

Author: Michael Millhollen Posted: 01 February 2016

Sekisui XenoTech recently fulfilled its largest order of human liver subcellular fractions to date. A large pharmaceutical customer ordered over 30,000 vials of microsomes, 5000 vials of S9 fractions and 5000 vials of cytosol.

Read more

XenoTech Hosts Bring Your Kids to Work Day

Author: Matt Beck Posted: 04 May 2015

XenoTech hosted "Bring your kids to work" day on April 23rd.

Read more

XenoTech Executives Take the Ice Bucket Challenge to Benefit ALS

Author: Matt Beck Posted: 22 August 2014

XenoTech employees raised over $1,400 in a single day to benefit the ALS Association. Watch the video of the Ice Bucket Challenge by clicking on the link to read more!

Read more

XenoTech Promotes Environmental Responsibility

Author: Christian Darabant Posted: 14 August 2014

XenoTech employees embrace Sekisui Environmental Week

Read more

XenoTech Company Halloween

Author: Matt Beck, Marketing Manager Posted: 01 November 2013

Happy Halloween, XenoTech style! Enjoy some pictures from this year's festivities.

Read more

Navigating the Transporter Wave of 2013: A Review of the Seven ITC Publications on Drug Transporters

Author: Greg Loewen, Principal Scientist - Drug Transport Posted: 28 August 2013

The International Transporter Consortium (ITC) issued seven papers in the July 2013 issue of Clinical Pharmacology & Therapeutics. These seven papers summarize the current understanding of transporters as related to possible drug-drug interactions (DDI). Although there is a mountain of research focusing on many aspects of drug transport such as the transport of endogenous compounds, transport regulation, characterizing transporter function, targeting transporters for disease treatment, etc. these papers outline the information most drug development companies need to know to investigate possible DDIs and properly label their compounds to prevent transporter based DDIs. Since the FDA issued the 2006 “Guidance for Industry, Drug Interaction Studies…” which described the in vitro assays suggested to predict possible P-gp related DDIs, the ITC published a white paper in 2010, the EMA issued the draft “Guideline on the Investigation of Drug Interactions” in 2010 and both the FDA and EMA published updated guidelines in 2012. The most recent guidelines described seven transporters that should be studied for possible DDIs, the in vitro assays used to study those transporters and decision trees to help decide if clinical studies were warranted to further elucidate possible DDIs. The seven papers published in July discuss the clinical importance of the MATE transporters, the clinical importance of OATP1B1 and BCRP polymorphisms, the applicability of the decision trees with some examples of compounds approved since the decision trees were published, in vitro methods used to study transporters, intercellular drug concentrations, kinetic parameters in conjunction with translational modeling, and why DDIs at the blood brain barrier are unlikely. A summary of the focus and main points of each of the seven papers can be found by clicking "Read More" below. To view our webinar on the seven papers click here

Read more